Samsung Biologics Co Stock Total Asset

207940 Stock   929,000  29,000  3.03%   
Samsung Biologics Co fundamentals help investors to digest information that contributes to Samsung Biologics' financial success or failures. It also enables traders to predict the movement of Samsung Stock. The fundamental analysis module provides a way to measure Samsung Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Samsung Biologics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Samsung Biologics Co Company Total Asset Analysis

Samsung Biologics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Total Asset

 = 

Tangible Assets

+

Intangible Assets

More About Total Asset | All Equity Analysis

Current Samsung Biologics Total Asset

    
  7.97 T  
Most of Samsung Biologics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Samsung Biologics Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Competition

Based on the latest financial disclosure, Samsung Biologics Co has a Total Asset of 7.97 T. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The total asset for all Republic of Korea stocks is significantly lower than that of the firm.

Samsung Total Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Samsung Biologics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Samsung Biologics could also be used in its relative valuation, which is a method of valuing Samsung Biologics by comparing valuation metrics of similar companies.
Samsung Biologics is currently under evaluation in total asset category among its peers.

Samsung Fundamentals

About Samsung Biologics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Samsung Biologics Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Samsung Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Samsung Biologics Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Samsung Biologics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Samsung Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Samsung Biologics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Samsung Stock

  0.66326030 Sk BiopharmaceuticalsPairCorr
  0.62298380 ABL BioPairCorr
The ability to find closely correlated positions to Samsung Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Samsung Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Samsung Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Samsung Biologics Co to buy it.
The correlation of Samsung Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Samsung Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Samsung Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Samsung Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Samsung Stock

Samsung Biologics financial ratios help investors to determine whether Samsung Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Samsung with respect to the benefits of owning Samsung Biologics security.